Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

NCT01734785 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

607

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Linagliptin
DRUG: Empagliflozin + Linagliptin
DRUG: Empagliflozin + Linagliptin
DRUG: Empagliflozin + Linagliptin
DRUG: Empagliflozin placebo + Linagliptin placebo
DRUG: Empagliflozin + Linagliptin

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]